Annexure 2 AX 03 / SOP 11-B/V6.1



(Annexure 6)

Serious Adverse Event Reporting Format (Biomedical Health Research)

INSTITUTIONAL ETHICS COMMITTEE (IEC)

Seth GS Medical College and KEM Hospital, Mumbai.

•	Project Registration No				
Title of study:					
Principal Investigator (Name, Designation and Affiliation):					
Davisiansk detaile :					
Participant details :	Candan	14/-:			
Initials and ID Age at the time of event	Gender	Weight:(Kgs)			
	Male ☐ Female ☐	Height:(cms)			
. Suspected SAE diagnosis:					
. Date of onset of SAE: dd mm yy	Describe the event ":				
olel ways 1,00					
Date of reporting SAE:					
. Details of suspected intervention causing SAE 20					
. Details of suspected intervention dusting SAE					
. Report type: Initial ☐ Follow-up ☐ Final ☐					
If Follow-up report, state date of Initial report	m yy				
. Have any similar SAE occurred previously in this study? If	yes, please provide details.	Yes □ No□			
Duration, setting, site, signs, symptoms, severity, criteria for regarding the ev Refers to research intervention including basic, applied and operational rese		restigational new drugs. If it is an			

academic clinical trial, mention name, indications, dosage, form and strength of the drug(s)

Version 1.0

7. In case of a multi-centric study, have any of the other study sites reported similar SAEs ?										
(Please list number of cases with details if available)										
8.	8. Tick whichever is applicable for the SAE: (Kindly note that this refers to the Intervention being evaluated and NC disease process) A.Expected event Unexpected event									
	B. Hospitalization		Increased Hospital Stay		Doath	_	Congonital anomaly/			
	nospitalization		Increased Hospital Stay		Death	П	Congenital anomaly/ birth defect			
	Persistent or significant disability/incapacity		Event requiring intervention (surgical or medical) to prevent SAE		Event which poses threat to life		Others			
	In case of death, state probable cause of death									
	much, and to whom)									
11.	Outcome of SAE Resolved	,	Ongoing \square	D	eath 🗆	C	Others (specify)			
12.	Provide any other releva	nt in	formation that can facili	tate a	ssessment of the case	such	as medical history			
13.	3. Provide details about Pl's final assessment of SAE relatedness to trial.									
	Signature of PI:				dd mm	УУ		Version 1.0		